Page last updated: 2024-12-09

2,4-dithiobiuret

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-dithiobiuret: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2758725
CHEMBL ID501562
SCHEMBL ID3077015
SCHEMBL ID24367774
MeSH IDM0050803

Synonyms (52)

Synonym
AKOS005445295
541-53-7
nsc7761
wln: suyzmyzus
nsc-7761
imidodicarbonodithioic diamide
dithiobiuret
imidodicarbonimidothioic diamide
thioimidodicarbonic diamide ([(h2n)c(s)]2nh)
2,4-dithiobiuret
urea, 2-thio-1-(thiocarbamoyl)-
biuret, dithio-
thioimidodicarbonic diamide ((h2n)c(s))2nh
rcra waste no. p049
thioimidodicarbonic diamide
allophanimidic acid, dithio-
hsdb 6047
dithioallophanimidic acid
thioimidodicarbonic diamide (((h2n)c(s))2nh)
nsc 7761
ai3-14762
biuret, 2,4-dithio-
einecs 208-784-8
rcra waste number p049
carbamothioylthiourea
STK370075
dicarbonodithioimidic diamide
dithiobiuret, 97%, solid
CHEMBL501562
dtxcid0014968
tox21_301949
dtxsid2034968 ,
NCGC00255476-01
cas-541-53-7
A829998
t40x2kxl53 ,
unii-t40x2kxl53
FT-0610224
SCHEMBL3077015
thioimidodicarbonicdiamide
2,4-dithiobiuret [mi]
2,4-dithiobiuret [hsdb]
dicarbonodithioimidic diamide #
[(h2-n)c(s)]2-nh
(carbamothioylamino)methanethioamide
STR04620
mfcd00037832
Q5283662
AMY831
D94742
SCHEMBL24367774
CS-0149932

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" All motor endpoints were decreased in a dosage- and time-dependent manner; the higher the dosage the longer the effects lasted."( The effects of 2,4-dithiobiuret on sensory and motor function.
Boyes, WK; Crofton, KM; Dean, KF; Hamrick, RC, 1991
)
0.63
" It was of interest to determine whether subtle changes in neuromuscular transmission are produced by DTB under dosing conditions in which gross muscle weakness is not apparent."( Acute alterations in murine neuromuscular transmission following exposure to a nonparalytic dose of dithiobiuret.
Atchison, WD; Spitsbergen, JM, 1990
)
0.28
" to rats for 4 days at a daily dosage of 1 mg/kg and the development of the lesion associated with neuromuscular dysfunction studied in hindlimb lumbrical muscles."( Dithiobiuret neurotoxicity: an ultrastructural investigation of the lesion in preterminal axons and motor endplates in the rat lumbrical muscle.
Jones, HB, 1989
)
0.28
" Dose and dosing regimen dependent changes in tissue distribution are evident for most tissues with the thyroid gland, lung, stomach and fat being the most affected."( Effects of dose and dosing regimen on tissue distribution and elimination kinetics of [14C] dithiobiuret in rats.
Atchison, WD; Dickins, J; Peterson, RE; Porter, WR, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency89.35840.002541.796015,848.9004AID1347398
GLI family zinc finger 3Homo sapiens (human)Potency61.13060.000714.592883.7951AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency64.75280.001022.650876.6163AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.58960.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.87240.000817.505159.3239AID1159527
pregnane X nuclear receptorHomo sapiens (human)Potency61.13060.005428.02631,258.9301AID1346982
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency44.93420.057821.109761.2679AID1159526; AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency59.42080.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency28.26890.042027.378961.6448AID743210; AID743228
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency43.27710.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency43.27710.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID394498Inhibition of Escherichia coli recombinant DNA gyrase-mediated supercoiling of relaxed pRSET A-DNA by agarose gel electrophoresis2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (55.17)18.7374
1990's10 (34.48)18.2507
2000's3 (10.34)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.72 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]